Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa double-blind randomized placebo-controlled dose-finding study of A3309 in dyslipidemia
2009-017878-21Phase 2Completed
- Sponsor
- Albireo Pharma
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elobixibat in dyslipidemia (3 arms), sponsored by Albireo Pharma. Primary endpoints: Change from baseline in total cholesterol and Change from baseline in LDL cholesterol. Started Dec 2009; status: completed.
02
Drugs
elobixibat
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on 2009-017878-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017878-21.